4.6 Article

Fibroblast Growth Factor 23 and Anemia in the Chronic Renal Insufficiency Cohort Study

期刊

出版社

AMER SOC NEPHROLOGY
DOI: 10.2215/CJN.03950417

关键词

-

资金

  1. National Kidney Foundation of Illinois
  2. National Institutes of Health (NIH), National Institute of Diabetes and Digestive and Kidney Disease (NIDDK) [K23DK094829, R01DK081374, K24DK093723, R01DK102438]
  3. American Heart Association [13FTF15920005]
  4. Strategically Focused Research Network Center Grant from the American Heart Association
  5. NIDDK [U01DK060990, U01DK060984, U01DK061022, U01DK061021, U01DK061028, U01DK060980, U01DK060963, U01DK060902]
  6. Perelman School of Medicine at the University of Pennsylvania Clinical and Translational Science Award NIH/National Center for Advancing Translational Sciences (NCATS) [UL1TR000003]
  7. Johns Hopkins University [UL1TR000424]
  8. University of Maryland General Clinical Research Center [M01 RR-16500]
  9. Clinical and Translational Science Collaborative of Cleveland from the NCATS component of the NIH [UL1TR000439]
  10. NIH Roadmap for Medical Research
  11. Michigan Institute for Clinical and Health Research [UL1TR000433]
  12. University of Illinois at Chicago Clinical and Translational Science Awards [UL1RR029879]
  13. Tulane Center of Biomedical Research Excellence for Clinical and Translational Research in Cardiometabolic Diseases [P20 GM109036]
  14. Kaiser Permanente NIH/National Center for Research Resources University of California San Francisco-Clinical and Translational Science Institute [UL1 RR-024131]

向作者/读者索取更多资源

Background and objectives Anemia is an early complication of CKD that is associated with increased morbidity and mortality. Prior data show associations between abnormal mineral metabolism markers and decreased erythropoiesis. However, few studies have investigated elevated fibroblast growth factor 23 as a risk factor for the development of anemia in patients with CKD. Design, setting, participants, & measurements We conducted a prospective cohort study of 3869 individuals with mildto severe CKD enrolled in the Chronic Renal Insufficiency Cohort Study between 2003 and 2008 and followed through 2013. We hypothesized that elevated baseline fibroblast growth factor 23 levels are associated with prevalent anemia, decline in hemoglobin over time, and development of incident anemia, defined as serum hemoglobin level,13 g/dl in men, serum hemoglobin level,12 g/dl in women, or use of erythropoietin stimulating agents. Results In the 1872 of 3869 individuals who had prevalent anemia at baseline, mean age was 58 (11) years old, and mean eGFR was 39 (13) ml/min per 1.73 m(2). Higher levels of fibroblast growth factor 23 were significantly associated with prevalent anemia (odds ratioper 1-SD increase innatural log-transformed fibroblast growth factor 23, 1.39; 95% confidence interval, 1.26 to 1.52), decline in hemoglobin over 4 years, and risk of incident anemia (hazard ratio per 1-SD increase in natural log-transformed fibroblast growth factor 23, 1.13; 95% confidence interval, 1.04 to 1.24; quartile 4 versus quartile 1: hazard ratio, 1.59; 95% confidence interval, 1.19 to 2.11) independent of demographic characteristics, cardiovascular disease risk factors, CKD-specific factors, and other mineral metabolism markers. The results of our prospective analyses remained unchanged after additional adjustment for time-varying eGFR. Conclusions Elevated fibroblast growth factor 23 is associated with prevalent anemia, change in hemoglobin over time, and development of anemia. Future studies are needed to elucidate the mechanisms for these associations.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.6
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据